There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HashiCorp (HCP – Research Report) and CureVac (CVAC – Research Report) with bullish sentiments.
HashiCorp (HCP)
In a report released yesterday, Gray Powell from BTIG maintained a Buy rating on HashiCorp, with a price target of $32.00. The company’s shares closed last Wednesday at $34.77.
According to TipRanks.com, Powell is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HashiCorp with a $35.46 average price target, representing a -0.9% downside. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $38.00 price target.
See the top stocks recommended by analysts >>
CureVac (CVAC)
Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on CureVac today and set a price target of $22.00. The company’s shares closed last Wednesday at $9.92.
According to TipRanks.com, Shu has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CureVac with a $17.80 average price target, implying an 80.9% upside from current levels. In a report released today, SVB Securities also initiated coverage with a Buy rating on the stock with a $13.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HCP:
- HashiCorp Tanks after Slashing Workforce, Cuts Down Spending
- HashiCorp Announces First Quarter Financial Results of Fiscal Year 2024
- Is HCP a Buy, Before Earnings?
- HashiCorp to Announce First Quarter Fiscal Year 2024 Financial Results June 7, 2023
- HashiCorp, Microsoft announces general availability of HCP Vault Plus on Azure
